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ABSTRACT 
Cisplatin (Cis diaminedichloro platinum) is the first platinum drug to be used as an anticancer drug, and it is widely used in the 
treatment of testicular, head, neck, ovarian and lung cancer. The use of Cisplatin is limited due to its intrinsic and acquired 
resistance and severe side effects such as chronic neurotoxicity and nephrotoxicity. The colloidal carriers such as emulsion, 
liposomes, polymeric nanoparticles have been extensively studied to overcome above limitations. The solid lipid nanoparticles 
(SLNs), amongst other colloidal carriers, were found to be an ideal carrier for lipophillic drug for better stability and release 
retardation. Cisplatin loaded solid lipid nanoparticles was prepared by microemulsion technique. Stearic acid was used as lipid. The 
other excipients were used as DPPG, Soya lecithin and Poloxamer P407 and acidic buffer  pH4. Probe sonication was used for 10 min 
at 79 Amplitude. Cisplatin SLNs Batch C13 showed particle size of 119.23±1.52 nm, Zeta potential of -37.33±2.47 mV, % Entrapment 
efficiency of  90.2 ± 2.1 %., % Drug loading capacity of 1.62 ± 1.34 %., The TEM study of optimized Cisplatin SLN illustrated the 
spherical shape of nanoparticles. Total release amount of Cisplatin was 82.62± 2.04 % after 48 hrs. The formulation performed 
kinetics study followed Peppas plot equation The SLNs of Cisplatin met all the requirements of a colloidal drug delivery system. 
They had particle size in nanosize; their size distribution was narrow and all the particles were in spherical shape and stable. 
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INTRODUCTION 
Cisplatin is a Antineoplastic agent used in the treatment of 
different malignancies. It is widely used in the treatment of 
testicular, head, neck, ovarian and lung cancer. The use of 
Cisplatin is limited due to its intrinsic and acquired 
resistance and severe side effects such as chronic 
neurotoxicity and nephrotoxicity.1 Cisplatin has limited 
bioavailability due to its poor aqueous solubility and it also 
shows harmful effects on various organs. Furthermore, the 
intravenous administration of Cisplatin produces adverse 
effects like renal failure, ototoxicity, loss of hearing, 
cerebral blindness, tubular necrosis and papilloedema. All 
these effects limit the amount of drug given to the patients. 
The colloidal carriers such as emulsion, liposomes, and 
polymeric nanoparticles have been extensively studied to 
overcome above limitations. The solid lipid nanoparticles 
(SLNs), amongst other colloidal carriers, were found to be 
an ideal carrier for lipophillic drug for better stability and 
release retardation. Further, the bioavailability of poorly 
soluble drug can be increased by incorporating them into 
SLNs.2  
Nano particulate drug delivery system may offer plenty of 
advantages over conventional dosage forms which include 
improved bioavailability, reduced toxicity, enhanced bio 
distribution and improved patient compliance3. Solid Lipid 
Nanoparticles (SLNs) introduced in 1991 represent an 
alternative and better carrier system to traditional 
colloidal carriers such as emulsions, liposomes and 
polymeric micro and nanoparticles. Colloidal drug delivery 
systems offer a number of advantages over conventional 
dosage forms. Due to their small particle size, colloidal 
preparations lend themselves to parenterals 
administration and may be useful as sustained release 
injections for the delivery to a specific organ or target site.4 
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Targeting the drug to the desired site of action would not 
only improve the therapeutic efficiency but also enable a 
reduction of the amount of drug which must be 
administered to achieve a therapeutic response, thus 
minimizing unwanted toxic effects. Lipid-based particulate 
delivery systems, like liposomes, micelles, nanocapsules, 
and solid lipid nanoparticles have been developed 
especially to solubilize poorly water-soluble and lipophillic 
drugs. These lipid-based systems have the advantage that 
comprises bio-derived and/or biocompatible lipids that 
often result in lower toxicity.2 This study is aimed to 
develop and characterize the Cisplatin loaded SLNs which 
are colloidal drug delivery in sustained manner with high 
degree of specificity. 
MATERIAL AND METHOD 
Material  
Cisplatin (Khandelwal Laboratories Pvt. Ltd. Thane), DPPG 
( Lipoid Germany) Stearic Acid , Poloxamer P-407, Soya 
Lecithin, citric acid, Potassium dihydrogen phosphate, 
Disodium hydrogen phosphate, sodium chloride ( Loba 
chemie Pvt. Ltd, Mumbai ) 
Method of preparation of Solid Lipid 
Nanoparticles 
Cisplatin loaded solid lipid nanoparticles were prepared by 
Microemulsion technique. In this technique Stearic acid 
melt at 800 C.  and the DPPG was melted at 1220 C and 
mixed with melted Stearic acid. To this mixture soya 
lecithin and Poloxamer P407 were added and stirred for 5 
min. Cisplatin was dissolved in acidic buffer pH 4 and 
incubated at 370 C for 30 min.  This solution was heated at 
80 0C. This aqueous phase was added to melted lipid phase. 
This solution was kept on probe sonicator for a period of 
10 min at 79 amplitude. Finally o/w emulsion was formed. 
This microemulsion was carefully added drop wise into 10 
ml ice cold acidic buffer pH 6,5 and 4 present in beaker 
with a continuous stirring at 2000 rpm on magnetic stirrer. 
The SLN dispersion was stirred for 3hr after addition of 
microemulsion.5,6 
 
Table 1: Formulation of Cisplatin SLNs  
Sr. No. Ingredients C11 C12 C13 
1.  Cisplatin 10 mg 10 mg 10 mg 
2.  Stearic acid 33.31 mg 33.31 mg 33.31 mg 
3.  Soya lecithin 500 mg 500 mg 500 mg 
4.  Poloxamer 407 28.50 mg 28.50 mg 28.50 mg 
5.  DPPG 15 mg 15 mg 15 mg 
6.  Acidic Buffer upto 20 ml (pH 6) 20 ml (pH 5) 20 ml (pH 4)  
 
 
Characterization of Cisplatin Solid Lipid 
Nanoparticles: 
1. Particle Size Analysis: 
The particle size and polydispersity index (PDI) of 
prepared solid lipid nanoparticle were determined using a 
Malvern Zetasizer ZS90 (Nanoseries Malvern Instrument). 
Each sample was diluted 10 times with distilled water to 
avoid multiscattering phenomena and is placed in 
disposable sizing cuvette. The ploydispersibility index was 
studied to determine the narrowness of particle size 
distribution. The size analysis of sample consisted of 3 
measurements and results were expressed as mean size ± 
Std. Deviation.5 
2. Zeta Potential: 
The zeta potential of prepared Cisplatin solid lipid 
nanoparticles was performed using Zeta meter. Zeta 
potential is as scientific term for electrokinetic potential in 
colloidal dispersion. Zeta potential is a key indicator of the 
stability of colloidal dispersions. The zeta potential of 
prepared Cisplatin solid lipid nanoparticles was 
determined using a Malvern Zetasizer ZS90 (Nanoseries 
Malvern Instrument). The pre concentrated Cisplatin SLNs 
1ml sample was diluted 10 times with distilled water in 10 
ml volumetric flask. From this solution 1 ml is placed in 
disposable zeta potential cuvette. 7 
 3 Determination of % Entrapment efficiency: 
Entrapment efficiency of Cisplatin loaded solid lipid 
nanoparticles was estimated by centrifugation method. In 
this method prepared solid lipid nanoparticles were placed 
in cooling centrifugation tube and centrifuged at 15000 
rpm for 45 min at 60C. The pellets were dissolved in 5 ml of 
methanol and evaporated using heating Mentle. Then 1 ml 
of OPDA and 2 ml of Phosphate buffer pH 7.4 were added. 
The mixture was then heated for 10 min and volume was 
adjusted with Dimethyl formamide upto 10 ml. Entrapped 
Cisplatin was determined using UV spectrophotometer at 
705 nm. The samples from supernatant were diluted 
before going for absorbance measurement. Encapsulation 
efficiency is also expressed as percent of drug trapped and 
was calculated using equation.8 
%EE= Total amount of drug incorporated in SLN / initial 
weight of drug X 100. 
4. Determination of % Drug Loading capacity:  
Loading capacity (LC %) can be calculated by dividing the 
amount of total entrapped drug by the total nanoparticle 
weight. In drug delivery, yield, given as a percent, is a 
reflection of the amount of drug delivered per amount 
encapsulated. Loading capacity helps you to deal with 
nanoparticles after their separation from the medium and 
to know their drug content. It is calculated using the 
following equation8 
%LC = [Entrapped Drug/Amount of drug + Lipid+ 
Excipient] * 100 
5. Surface Morphology:  
TEM determines the particle size with or without staining. 
SEM uses electrons transmitted from the specimen surface, 
while TEM uses electrons transmitted through the 
specimen. TEM allows visualization of SLNs after freeze 
fracturing and freeze substitution. Transmission Electron 
Microscopy was used to visualize the morphology of solid 
lipid nanoparticle. By using TEM, various characteristics 
like particle size, shape and internal structure of 
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nanoparticulate carriers system can be efficiently 
evaluated.9 
6. In-Vitro Drug Release: 
In-vitro drug release of prepared cisplatin solid lipid 
nanoparticles was performed by using Dialysis bag.The 
release of Cisplatin from the solid lipid nanoparticles was 
measured in triplicate in Phosphate Buffer Saline pH 7.4.  2 
mg equivalent cisplatin SLN were taken in a dialysis bag 
and both the end of dialysis bag were closed and placed in 
beaker containing 75ml PBS pH 7.4. This dialysis bag was 
arranged in such a way that it just touches the surface of 
buffer solution. The whole set up was placed on a magnetic 
stirrer which was rotated at 50rpm. Temperature of buffer 
was maintained at 37±10C. 2 ml aliquots of release medium 
were withdrawn at a time interval of 0.5, 1, 2, 4, 8, 12, 24 
and 48 hrs. To maintain the sink condition, same volume of 
dissolution media was added. The aliquots were 
centrifuged at 3000rpm for 5 to 10 min. at room 
temperature. Supernatant was diluted with 2 ml phosphate 
buffer PH 7.4 and 1 ml OPDA solution. This solution was 
heated at 100∘C for 15 min in order to get light green 
colored solution and volume was adjusted with Dimethyl 
Formamide to 10 ml. This was estimated by UV Visible 
spectrophotometer at 704 nm. The concentration of drug 
was calculated from straight line equation obtained from 
standard curve of Cisplatin.10 
The data obtained from In-vitro release was subjected to 
kinetic study. 10 
7. Stability study of Optimized Cisplatin SLNs: The 
purpose of stability testing is to provide information on 
how the quality of drug product varies with time under the 
influence of variety of environmental factors such as 
temperature, humidity and light and to establish a shelf life 
for drug product at recommended storage conditions.10 
Procedure: From the different SLN batches, Formulation 
C13 was tested for stability studies. Formulation C13 was 
divided into 3 sample sets and stored at 40± 10C, 250±20C 
and 60% ± 5% RH, 400±2 0C and 75%± 5 % RH. 
 After one month, particle size, entrapment efficiency of 
selected formulations was determined. 
RESULT AND DISCUSSION 
1. Particle size Analysis of Cisplatin SLNs:  
The particle size is the most important property for in vivo 
integrity and biological fate of nanoparticles. Development 
of carriers with appropriate size plays an important role in 
the field of drug delivery. It is stated that nanoparticles in 
the range of 100-200nm have the highest potential to 
extend the circulation time in the blood stream, because 
they are small enough to avoid selective uptake in the liver. 
The vasculature of cancer cells is leaky unlike the normal 
cells. Small size of nanoparticles allows them to permeate 
through this leaky vasculature and to be retained in the 
tumour cells. This phenomenon improves the intracellular 
accumulation and localization of SLNs in tumor without 
affecting normal cells. All the batches produced 
nanoparticles in the size range between 100-200 nm. 
Amongst them the particle size of batch C13 was found to 
be 119 nm and was, therefore, optimized and selected for 
In-vitro drug release.  Out of   three graphs of particle size 
of each batch of Cisplatin SLNs one less particle size of 
graph showed in Figure 1,2,3. 
 
Table 2: Characterization of Cisplatin SLNs 
Sr. No Batch Average Particle 
size 
PDI Zeta Potential 
(mV) 
% Entrapment 
efficiency 
% Drug Loading 
Capacity 
1.  C11 167.4 ±1.15 0.411±0.06 -30.26±0.66 42.82 ±3.15 0.85 ± 0.03 
2.  C12 157.1±3.25 0.321±0.03 -33.53±1.53 65.14±0.12 1.38 ± 0.02 
3.  C13 119.23±1.52 0.416±0.01 37.33±2.47 90.2 ± 2.1 1.62  ± 1.34 
 
Batch C11: 
 
Figure 1: Particle Size and PDI of Batch C11 Cisplatin SLNs 
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Batch C12: 
 
Figure 2: Particle Size and PDI of Batch C12 Cisplatin SLNs 
Batch C13: 
 
Figure 3: Particle Size and PDI of Batch C13 Cisplatin SLNs 
2. Determination of Zeta potential:  
The zeta potentials of all the batches were greater than 30mV with negative charge indicating the stability of the 
formulations. The highest stability as measured by the zeta potential was shown by batch C13 which was formulated at pH 4. 
Moreover, the anionic lipid DPPG might have added to the negative charge thereby improving the stability of formulation. 
Out of the three graphs of Zeta Potential of Each batch of Cisplatin SLNs, one graph  which is high zeta potential value showed 
in Figure 4,5and 6. 
Batch C11: 
 
Figure 4: Zeta Potential of Batch C11 Cisplatin SLN 
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Batch C12 
 
Figure 5: Zeta Potential of Batch C12 Cisplatin SLN 
Batch C13 
 
Figure 6: Zeta Potential of Batch C13 Cisplatin SLN 
   
3. % Entrapment Efficiency:  
Drug entrapment efficiency is an important property in 
drug loaded nanocarriers and directly affects the 
therapeutic effect of system. The entrapment efficiencies 
have been shown in table no. 2. The results show that the 
amount of drug entrapped was more due to the DPPG, soya 
lecithin  and  three times Stearic acid increased acidic 
buffer pH 4.The entrapment efficiency of pH 5 and 6 
batches showed less entrapment than pH 4 batch C13.The 
effect of acidic pH buffer on the % Entrapment efficiency. 
The effect on entrapment was observed in batch C13 i.e. 
90.2 ± 2.1 %. The higher the encapsulation capacity of 
nanoparticles the larger the amount of drug released at the 
tumor site.  
4. % Drug Loading Capacity: 
The % Drug loading capacity of Cisplatin C13 was found to 
be 1.62 ± 1.34 %. It was shows a good result. 
5. Surface Morphology: 
The TEM study of optimized Cisplatin SLN illustrated the 
spherical shape of nanoparticles. The TEM image of the 
nanoparticles is depicted in Figure No.7.It is evident from 
the image that the particles were spherical in shape with 
narrow size distribution and no aggregation. Particles of 
optimized Cisplatin SLN formulation were of nanosize. The 
surfaces of particles are smooth moreover their integrity 
was found to be intact. 
 
Figure 7: TEM of Cisplatin SLN
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6. In-vitro drug release of Cisplatin Solid lipid Nanoparticles: 
Table 3: In-vitro release profile of Cisplatin SLN (Formulation C13) 
Sr. No 
Time 
hr 
% Cumulative Drug Release % Cumulative 
Average ±S.D 
SEM 
I II III 
1.  0 0 0 0 0 0 
2.  0.5 5.06 7.07 4.05 5.39± 1.53 0.88 
3.  1 8.81 7.20 11.09 9.03± 1.95 1.12 
4.  2 13.03 15.24 18.26 15.51± 2.62 1.51 
5.  4 24.43 26.37 30.12 26.97± 2.89 1.66 
6.  8 42.86 40.31 45.74 42.97± 2.71 1.56 
7.  12 60.95 64.17 66.99 64.03± 3.02 1.74 
8.  24 75.03 77.04 73.12 75.06± 1.96 1.13 
9.  48 84.41 83.07 80.39 82.62± 2.04 1.17 
 
 
       Figure 8: In-Vitro Release Profile of Cisplatin SLNs 
Batch C13 
In-vitro drug release profile of Cisplatin solid lipid 
nanoparticles was performed in order to evaluate the 
stability and release behavior of Cisplatin SLN. The 
prepared SLN showed a long term stable drug release 
profile up to 48hrs. Total release amount of Cisplatin was 
82.62± 2.04 % after 48 hrs Thus, Cisplatin SLN may serve 
as stable nanoparticles for a longer period thereby 
increasing drug accumulation into tumor site. 
Treatment of Kinetic release study: 
Table 4: Cisplatin SLNs Model Fitting Profile 
Cisplatin 
SLN 
Zero 
Order 
First 
Order 
Peppas Higuchi 
R2 0.7517 0.8338 0.9663 0.9298 
 
The results of In-vitro release study were treated by 
mathematical model. Cumulative percentage drug release 
of C3 batch after 48 hrs was shown 82.62%. The 
formulation followed Peppas plot equation. This indicates 
that the Cisplatin nanoparticle followed more than one 
type of release phenomenon and it appeared to be by the 
Non Fickian diffusion control mechanism. 
 
Stability Study: 
Table 5: Stability Study of Selected formulation C13 
Formulation C13 40± 10C 250±20C and 60% ± 5% RH 400±2 0C and 75%± 5 % RH 
% Entrapment efficiency 89.04±1.26 87.32±1.58 86.25±2.22 
Particle Size 120.2±2.24 122.5±1.65 123.4±3.02 
 
Stability study of the prepared Cisplatin solid lipid 
nanoparticles C13 were carried out, by storing the 
formulation C13 at  40± 10C, 250±20C and 60% ± 5% RH, 
and 400±2 0C and 75%± 5 % RH in humidity control oven 
for month. The %Entrapment efficiency and Particle size 
were carried out. The results % Entrapment efficiency and 
Particle size at different storage condition are shown in 
Table 5.The comparing this data with the previous data of 
C13 it was observed that there is slight increase in Particle 
size and little Decrease in the % Entrapment efficiency. 
 
 
Figure 9: Particle size of Cisplatin SLNs of batch C13 after stability  
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CONCLUSION 
The Cisplatin loaded solid lipid nanoparticles met all the 
requirements of a colloidal drug delivery system. They had 
particle size in nanosize; their size distribution was narrow 
and all the particles were in spherical shape. The percent 
entrapment efficiency and percent drug loading capacities 
were in the acceptable limits. Moreover, the In-vitro 
release pattern revealed that they served the purpose of 
being a sustained drug delivery system 
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